Low intensity warfarin: Is it clinically useful in venous thromboembolism management?

British Journal of Haematology

Volumn 127, Issue 2, 2004, Pages 155-158

  Bauer, Kenneth A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Anticoagulation; Clinical trials; Deep venous thrombosis; Venous thromboembolism; Warfarin

Indexed keywords

ANTIVITAMIN K; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INTERNATIONAL STANDARD UNIT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT SELECTION; RECURRENCE; THROMBOEMBOLISM; WARFARIN;

EID: 5644271563     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05174.x     Document Type: Review

References (22)

1. Agnelli, G. (2004) Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. Journal of Thrombosis and Haemostasis, 2, 1038-1040.
2. Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G., Ageno, W. and the Warfarin Optimal Duration Italian Trial Investigators (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. New England Journal of Medicine, 345, 165-169.
3. Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M.R., Miccio, M., Imberti, D., Poggio, R., Ageno, W., Pogliani, E., Porro, F., Zonzin, P. and the Warfarin Optimal Duration Italian Trial Investigators (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Annals of Internal Medicine, 139, 19-25.
4. Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D. & Matchar, D. (2001) Managing oral anticoagulant therapy. Chest, 119, 22S-38S.
5. Bauer, K.A. (2001) The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Annals of Internal Medicine, 135, 367-373.
6. Beyth, R.J., Quinn, L.M. & Landefeld, C.S. (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. American Journal of Medicine, 105, 91-99.
7. Büller, H.R. & Prins, M.H. (2003) Secondary prophylaxis with warfarin for venous thromboembolism. New England Journal of Medicine, 349, 702-704.
8. Fihn, S.D., Callahan, C.M., Martin, D.C., McDonell, M.B., Henikoff, J.G. & White, R.H. (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Annals of Internal Medicine, 124, 970-979.
9. Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A.G., McLoughlin, D., Dodd, P., Thomas, M., Raskob, G. & Ockelford, P. (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 307, 1676-1681.
10. Hyers, T.M., Agnelli, G., Hull, R.D., Morris, T.A., Samama, M., Tapson, V. & Weg, J.G. (2001) Antithrombotic therapy for venous thromboembolic disease. Chest, 119, 176S-193S.
11. Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M.J., Anderson, D.R., Turpie, A.G., Green, D., Ginsberg, J.S., Wells, P., MacKinnon, B. & Julian, J.A. (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New England Journal of Medicine, 340, 901-907.
12. Kearon, C., Ginsberg, J.S., Kovacs, M.J., Anderson, D.R., Wells, P., Julian, J.A., MacKinnon, B., Weitz, J.I., Crowther, M.A., Dolan, S., Turpie, A.G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S.R., Kassis, J., Rodger, M., Hambleton, J., Gent, M. and for the Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. New England Journal of Medicine, 349, 631-639.
13. Kovacs, M.J. (2004) Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. Journal of Thrombosis and Haemostasis, 2, 1041-1043.
14. Kyrle, P.A., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A. & Eichinger, S. (2004) The risk of recurrent venous thromboembolism in men and women. New England Journal of Medicine, 350, 2558-2563.
15. Levine, M.N., Hirsh, J., Gent, M., Arnold, A., Warr, D., Falanga, A., Samosh, M., Bramwell, V., Pritchard, K.I., Stewart, D. & Goodwin, P. (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 343, 886-889.
16. Millenson, M.M., Bauer, K.A., Kistler, J.P., Barzegar, S., Tulin, L. & Rosenberg, R.D. (1992) Monitoring 'mini-intensity' anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1 + 2 levels. Blood, 79, 2034-2038.
17. Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., Devoto, G., Berrettini, M., Moselesi, S. on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. (1996). Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, 348, 423-428.
18. Palareti, G., Hirsh, J., Legnani, C., Manotti, C., D'Angelo, A., Pengo, V., Moia, M., Guazzaloca, G., Moselesi, S. & Coccheri, S. (2000) Oral anticoagulation in the elderly: a nested, prospective case-control study. Archives of Internal Medicine, 160, 470-478.
19. Prandoni, P., Lensing, A.W.A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A.M., Polistena, P., Bernardi, E. & Prins, M.H. (1996) The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine, 125, 1-7.
20. Ridker, P.M. (2004) Long-term low-dose warfarin use is effective in the prevention of venous thromboembolism: yes. Journal of Thrombosis and Haemostasis, 2, 1034-1037.
21. Ridker, P.M., Goldhaber, S.Z., Danielson, E., Rosenberg, Y., Eby, C.S., Deitcher, S.R., Cushman, M., Moll, S., Kessler, C.M., Elliott, C.G., Paulson, R., Wong, T., Bauer, K.A., Schwartz, B.A., Miletich, J.P., Bounameaux, H., Glynn, R.I. and the PREVENT Investigators (2003) Long-term, low-intensity warfarin for the prevention of recurrent venous thromboembolism. New England Journal of Medicine, 348, 1425-1434.
22. Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S.-G., Nordlander, S., Lärfars, G., Leijd, B., Linder, O., Loogna, E. and the Duration of Anticoagulation Trial Study Group (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New England Journal of Medicine, 336, 393-398.